CLINICAL WORK
UCSF At-Risk for T1D Clinic
By detecting early signs of T1D and taking proactive measures, Dr. Quandt and her team can slow its progression and delay the need for insulin therapy. Whether due to family history or a positive autoantibody test, early detection is key. Treatments, such as the immune therapy teplizumab (Tzield), can slow T1D progression, giving patients more time before needing to start insulin therapy. Early detection can make a lasting difference in your health or the health of your loved one.
Endocrine Clinical & Translational Research Center (ECTRC)
Dr. Quandt sits on the Executive Committee of the ECTRC, a center of excellence in clinical research at the Division of Endocrinology to conduct investigator-initiated and industry-sponsored clinical research trials, ensuring consistent, uniform access to clinical research coordinators, clinical space, and wide variety of biospecimen collection including blood, serum, adipose, bone, and teeth samples from a broad range of patient populations.
Human Studies
Dr. Quandt is also involved in various human studies led out of Anderson lab, including Autoimmunity Study, which explores the genetics of tissue specific autoimmunity; Autoimmunity and Diabetes Genetics Study, on the identification of novel diabetes genes through next generation sequencing; and the Endocrine Biobank Study, a study of the characteristics and causes of Endocrine Disorders.